Pharma Promotion / Incidents by company
Incidents by pharmaceutical company
Litigation, court decisions, sanctions and code rulings since 1990, by company: when, where, what, outcome and amount (42 companies, 596 incidents).
| Company | Incidents | Jurisdictions | Years | Amounts (indicative) |
|---|---|---|---|---|
| Pfizer | 59 | European Union・United Kingdom・United States | 1993〜2025 | GBP 63.0 m / USD 8.58 bn |
| Johnson & Johnson | 47 | Australia・United States | 1995〜2026 | USD 30.32 bn |
| Purdue Pharma | 42 | United States | 2001〜2026 | USD 14.51 bn |
| Eli Lilly | 40 | Canada・United States | 1995〜2026 | USD 2.71 bn |
| Novartis | 38 | European Union・Japan・United Kingdom・United States | 2003〜2026 | USD 4.09 bn |
| GSK | 33 | China・European Union・United Kingdom・United States | 1998〜2023 | GBP 37.0 m / USD 11.00 bn |
| Insys | 27 | United States | 2016〜2025 | USD 273.0 m |
| Bristol Myers Squibb | 26 | United States | 1990〜2023 | USD 1.41 bn |
| Sanofi | 24 | United States | 1997〜2026 | USD 313.3 m |
| AstraZeneca | 22 | China・United States | 2003〜2026 | USD 929.4 m |
| Amgen | 21 | United States | 2008〜2025 | USD 1.94 bn |
| Abbott | 19 | United Kingdom・United States | 2001〜2026 | USD 5.34 bn |
| Teva | 19 | European Union・United States | 2010〜2024 | EUR 462.6 m / USD 2.87 bn |
| Endo | 16 | United States | 2014〜2024 | USD 4.13 bn |
| Merck & Co. (MSD) | 16 | Switzerland・United Kingdom・United States | 2000〜2022 | USD 10.11 bn |
| Bayer | 15 | United States | 2014〜2026 | USD 11.87 bn |
| Roche | 14 | Switzerland・United Kingdom・United States | 2000〜2024 | — |
| Forest Laboratories | 13 | United States | 1993〜2019 | USD 351.0 m |
| Mallinckrodt | 11 | United States | 2012〜2022 | USD 881.9 m |
| Astellas | 10 | United Kingdom・United States | 2014〜2023 | USD 232.3 m |
| Novo Nordisk | 10 | European Union・United Kingdom・United States | 2009〜2025 | USD 92.7 m |
| Takeda | 10 | United States | 2013〜2026 | USD 2.38 bn |
| AbbVie | 7 | United Kingdom・United States | 2010〜2022 | USD 2.42 bn |
| Biovail | 7 | United States | 2001〜2010 | USD 10.0 m |
| Indivior | 6 | United States | 2019〜2020 | USD 1.20 bn |
| CSL | 4 | United States | 2016〜2018 | — |
| Dr. Reddy's | 4 | United States | 2014〜2018 | USD 5.0 m |
| Mylan / Viatris | 4 | United States | 2006〜2026 | USD 930.0 m |
| UCB | 4 | European Union・United States | 1999〜2020 | EUR 10.4 m / USD 68.0 m |
| Boehringer Ingelheim | 3 | European Union・United States | 2012〜2023 | USD 745.0 m |
| Cephalon | 3 | United States | 2008〜2015 | USD 432.5 m |
| Gilead | 3 | United States | 2019〜2025 | USD 299.0 m |
| Grifols | 3 | Canada・United States | 2024〜2025 | — |
| Lundbeck | 3 | European Union・United States | 2013〜2026 | EUR 93.8 m / USD 122.6 m |
| Regeneron | 3 | United States | 2020〜2025 | — |
| Biogen | 2 | United States | 2020〜2022 | USD 922.0 m |
| Hanmi | 2 | Korea | 2016〜2018 | — |
| Serono | 2 | United States | 2005〜2011 | USD 748.3 m |
| Bausch Health | 1 | United States | 2024〜2024 | — |
| Daiichi Sankyo | 1 | United States | 2015〜2015 | USD 39.0 m |
| Servier | 1 | European Union | 2021〜2021 | EUR 2.7 m |
| Sun Pharma | 1 | United States | 2017〜2017 | — |